<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; ANDS</title>
	<atom:link href="http://www.stockbloghub.com/tag/ands/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Sun, 20 May 2012 20:27:31 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(ANDS) Anadys Pharmaceuticals Announces Good News For Hepatitis Candidate</title>
		<link>http://www.stockbloghub.com/2010/05/24/ands-anadys-pharmaceuticals-announces-good-news-for-hepatitis-candidate/38219</link>
		<comments>http://www.stockbloghub.com/2010/05/24/ands-anadys-pharmaceuticals-announces-good-news-for-hepatitis-candidate/38219#comments</comments>
		<pubDate>Tue, 25 May 2010 03:52:38 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Anadys Pharmaceuticals Inc]]></category>
		<category><![CDATA[ANDS]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=38219</guid>
		<description><![CDATA[Anadys Pharmaceuticals Inc. (ANDS) announced that its lead candidate, ANA598, which is being developed for treating patients with hepatitis C virus (HCV) infections, has met key goals in a mid-stage study. The study saw HCV patients being treated with ANA598 in combination with pegylated interferon and ribavirin ? the current standard of care (SOC) ? at a 400 mg (twice daily) dosage level and analyzed at 12 weeks. The interim data from the 12-week analysis revealed that 75% patients who received the HCV drug in combination with the SOC showed undetectable traces of the virus as against 63% of those treated with placebo plus SOC. Furthermore, 73% patients treated with the 200 mg dose of ANA598 showed undetectable levels of the virus after 12 weeks. The mid-stage study is designed ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/05/24/ands-anadys-pharmaceuticals-announces-good-news-for-hepatitis-candidate/38219/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ANDS) Anadys Pharmaceuticals Reports Positive Study Data</title>
		<link>http://www.stockbloghub.com/2010/04/18/ands-anadys-pharmaceuticals-reports-positive-study-data/34101</link>
		<comments>http://www.stockbloghub.com/2010/04/18/ands-anadys-pharmaceuticals-reports-positive-study-data/34101#comments</comments>
		<pubDate>Mon, 19 Apr 2010 01:26:15 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Anadys Pharmaceuticals Inc]]></category>
		<category><![CDATA[ANDS]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=34101</guid>
		<description><![CDATA[Anadys Pharmaceuticals Inc. (ANDS) announced that its lead candidate, ANA598, which is being developed for treating patients with hepatitis C virus (HCV) infections, has met its key goals in a mid-stage study. The study saw HCV patients being treated with ANA598 in combination with pegylated interferon and ribavirin &#8211; the current standard of care (SOC) &#8211; at a 400 mg twice daily dosage level. The preliminary analysis of data revealed that 72% of the patients treated with ANA598 reported undetectable levels of virus after eight weeks of the study as against 38% of those treated with placebo plus SOC. The preliminary analysis of results through eight weeks also revealed that the ANA598 400 mg plus SOC combination was well-tolerated. Anadys stated that conclusions regarding safety and tolerability of the candidate ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/18/ands-anadys-pharmaceuticals-reports-positive-study-data/34101/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ANDS) Anadys Pharmaceuticals Drug Meets Key Study Goals</title>
		<link>http://www.stockbloghub.com/2009/12/18/ands-anadys-pharmaceuticals-drug-meets-key-study-goals/23216</link>
		<comments>http://www.stockbloghub.com/2009/12/18/ands-anadys-pharmaceuticals-drug-meets-key-study-goals/23216#comments</comments>
		<pubDate>Fri, 18 Dec 2009 23:40:30 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Anadys Pharmaceuticals Inc]]></category>
		<category><![CDATA[ANDS]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[RVR]]></category>
		<category><![CDATA[SOC]]></category>
		<category><![CDATA[Stoneleigh Partners Acquisition Corporation]]></category>
		<category><![CDATA[White River Capital Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=23216</guid>
		<description><![CDATA[Anadys Pharmaceuticals Inc. (ANDS) announced that its lead candidate, ANA598, which is being developed for treating patients with hepatitis C virus (HCV) infections has met its key goals in a mid-stage study. The study saw HCV patients being treated with ANA598 in combination with pegylated interferon and ribavirin &#8211; the current standard of care (SOC) &#8211; at a 200 mg bid dosage level and analyzed at four weeks. The drug was generally well tolerated. No discontinuations because of serious adverse events were reported even though eight patients, seven mild and one moderate, developed rash in the interim analysis. The interim data from the four-week analysis revealed that 56% patients who received the HCV drug in combination with the SOC showed undetectable traces of the virus, Rapid Virological Response (RVR), at ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/18/ands-anadys-pharmaceuticals-drug-meets-key-study-goals/23216/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ANDS) Anadys Begins Mid-Stage Trial</title>
		<link>http://www.stockbloghub.com/2009/09/11/ands-anadys-begins-mid-stage-trial/14986</link>
		<comments>http://www.stockbloghub.com/2009/09/11/ands-anadys-begins-mid-stage-trial/14986#comments</comments>
		<pubDate>Fri, 11 Sep 2009 23:12:11 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Anadys Pharmaceuticals Inc]]></category>
		<category><![CDATA[ANDS]]></category>
		<category><![CDATA[Schering-Plough Corp.]]></category>
		<category><![CDATA[SGP]]></category>
		<category><![CDATA[Valeant Pharmaceuticals International]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>
		<category><![CDATA[VRX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=14986</guid>
		<description><![CDATA[Yesterday, Anadys Pharmaceuticals Inc. (ANDS) started a 12-week phase II trial of its ANA598 for hepatitis C patients. ANA 598 will be evaluated in combination with interferon-alpha and ribavirin (current standard of care) in the mid-stage study. Data from the trial is expected to be released at the end of this year and in the first two quarters of 2010. A total of 90 patients are planned to be enrolled in the study, with 30 patients receiving ANA598 and 15 receiving placebo at each dose level. The study would test 200 mg and 400 mg doses of the drug. In order to maximize early viral suppression, each patient would receive two 800 mg doses on the first day. The study would be conducted at various sites in the U.S. Chronic ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/11/ands-anadys-begins-mid-stage-trial/14986/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

